Owen B. Ivan, BS, Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson, MS.

Chelsea Mockbee, MD, FAAD, Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson, MS.

Robert T. Brodell, MD, FAAD, Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson, MS.

Vinayak K. Nahar, MD, PhD, MS, Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson, MS; and Department of Preventive Medicine, School of Medicine/John D. Bower School of Population Health, University of Mississippi Medical Center, Jackson, MS.

Robert T. Brodell has participated in multicenter clinical trials with CorEvitas (formerly Corrona) Psoriasis Registry and Novartis (stock: Veradermics, Inc.). He is also an associate editor of the Journal of the American Academy of Dermatology, faculty advisor for the American Medical Student Research Journal, and editor-in-chief of Practice Update: Dermatology and serves as a staff dermatologist at the G.V. (Sonny) Montgomery VA Hospital in Jackson, MS. Owen B. Ivan, Chelsea Mockbee, and Vinayak K. Nahar declare no conflict of interest.

Correspondence concerning this article should be addressed to Vinayak K. Nahar, MD, PhD, MS, Department of Dermatology, School of Medicine, University of Mississippi Medical Center, 2500 North State Street – L216, Jackson, MS 39216. E-mail: [email protected]